Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & ObjectivesMission StatementEditorial BoardPartnership & OutreachForthcoming Meetings
What will members gain?

Download Now: New Slide Deck Programme

Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.

Find out more »
Download NowUNIQUE FREE APPAdvances in lipid lowering - a clinical guide
eBook
Most viewed

Hot Topics

13th Closed Virtual Meeting of the Editorial Board of PCSK9 Forum

 
Keynote – Post CVD event depression: The prequel and sequel

Prof. David L. Hare presents an objective overview of the evidence for depression and cardiovascular disease, taking the following questions in turn. Does depression cause cardiovascular disease? And does cardiovascular disease cause depression?
Watch the webcast
 
Keynote – Lipoprotein(a): “The proof of the pudding is in the trial”

Prof. Joseph L. Witztum overviews the evolving evidence for lipoprotein(a) as a cardiovascular risk factor, culminating in the Lp(a)HORIZON outcomes study. If positive, findings from this trial will have important public health implications.
Watch the webcast

 

From the Editors

SAMSON’s undoing is in the details

Prof. Robert S. Rosenson, Mount Sinai Icahn School of Medicine, New York, USA discusses results from the SAMSON trial of symptoms reported with statin treatment.

Read the report

 

Other related reports:

Statin intolerance back in the news: ASCOT-LLA report argues for a nocebo effect
Read the report

Statin intolerance – 50% higher risk of recurrent heart attack in statin intolerant patients
Read the report

Adverse effects of long-term statin therapy: New statement from the EAS Consensus Panel
Read the report

ACC 2017

Meet our Editorial Board

View all our Editorial Board Prof John ChapmanResearch Professor at the University of Pierre and Marie Curie Prof Henry GinsbergDirector, Irving Institute for Clinical and Translational Research Dr Michel FarnierClinician based at Point Medical, Dijon, France Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology